author-photo

Omid Hamid

Cedars-Sinai Medical Center

22

Papers

475

Citations

Citation Trend

Filter By

Papers (17) Sort By

Journal Conference Others

LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trial.

2021 Investigational New Drugs
Show All
- Source
- Cite
- Save
Citations (4)
Avelumab in patients with previously treated Merkel cell carcinoma (JAVELIN Merkel 200): Updated overall survival data after more than five years of follow up.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (1)
KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation.

2021 European Journal of Cancer
Show All
- Source
- Cite
- Save
Citations (0)
Immune adverse events (irAEs) with adjuvant ipilimumab in melanoma, use of immunosuppressants and association with outcome: ECOG-ACRIN E1609 study analysis.

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (2)
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (10)
Development and Validation of a Modified Pathologic Nodal Classification System for Cutaneous Melanoma.

2021 JAMA Surgery
Show All
- Source
- Cite
- Save
Citations (1)
Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence.

2021 Journal for ImmunoTherapy of Cancer
Show All
- Source
- Cite
- Save
Citations (1)
Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Phase I experience with first in class TnMUC1 targeted chimeric antigen receptor T-cells in patients with advanced TnMUC1 positive solid tumors.

2021 Journal of Clinical Oncology
Show All
- Source
- Cite
- Save
Citations (0)
Abstract CT033: Inducible T cell costimulatory (ICOS) receptor agonist, feladilimab (FE), alone and in combination (combo) with pembrolizumab (PE): Results from INDUCE-1 relapsed/refractory (R/R) melanoma expansion cohorts (EC)

2021 Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)